Thromboxane A2 promotes soluble CD40 ligand release from human platelets

Atherosclerosis

Volumn 209, Issue 2, 2010, Pages 415-421

  Enomoto, Yukiko ^a   Adachi, Seiji ^a   Matsushima Nishiwaki, Rie ^a   Doi, Tomoaki ^a   Niwa, Masayuki ^a   Akamatsu, Shigeru ^b   Tokuda, Haruhiko ^a,c   Ogura, Shinji ^a   Yoshimura, Shinichi ^a   Iwama, Toru ^a   Kozawa, Osamu ^a  

^a GIFU UNIVERSITY   (Japan)

^b Matsunami General Hospital   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Aspirin; Atherosclerosis; Platelets; Soluble CD40 ligand; Thromboxanes

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CD40 LIGAND; DIURETIC AGENT; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IX; GLYCOPROTEIN V; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RISTOCETIN; THROMBOXANE A2; UNCLASSIFIED DRUG;

AGED; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; THROMBOCYTE; UPREGULATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; AGED; ASPIRIN; ATHEROSCLEROSIS; BLOOD PLATELETS; CAROTID ARTERY DISEASES; CD40 LIGAND; FEMALE; HUMANS; MALE; MAP KINASE KINASE 4; METHACRYLATES; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRAZOLES; RISTOCETIN; THROMBOXANE A2;

EID: 77950021632     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.10.024     Document Type: Article

References (49)

1. Libby P. Inflammation in atherosclerosis. Nature 2000, 420:686-874.
2. Henn V., Slupsky J.R., Gräfe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
3. Davì G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
4. Furman M.I., Krueger L.A., Linden M.D., et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004, 43:2319-2325.
5. Mach F., Schönbeck U., Sukhova G.K., Atkinson E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 1998, 394:200-203.
6. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104-1111.
7. Garlichs C.D., Eskafi S., Raaz D., et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001, 86:649-655.
8. Garlichs C.D., Kozina S., Fateh-Moghadam S., et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003, 34:1412-1418.
9. Santilli F., Davì G., Consoli A., et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006, 47:391-397.
10. Harding S.A., Sommerfield A.J., Sarma J., et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004, 176:321-325.
11. Novo S., Basili S., Tantillo R., et al. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke 2005, 36:673-675.
12. Schönbeck U., Varo N., Libby P., Buring J., Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104:2266-2268.
13. de Lemos J.A., Zirlik A., Schönbeck U., et al. Association between soluble CD40 ligand, atherosclerotic risk factors, and subclinical atherosclerosis: results from Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005, 25:2192-2196.
14. Nannizzi-Alaimo L., Alves V.L., Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003, 107:1123-1128.
15. Berndt M.C., Shen Y., Dopheide S.M., Gardiner E.E., Andrews R.K. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001, 86:178-188.
16. Dong J.F., Berndt M.C., Schade A., et al. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood 2001, 97:162-168.
17. Garcia A., Quinton T.M., Dorsam R.T., Kunapuli S.P. Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. Blood 2005, 106:3410-3414.
18. Tamura N., Yoshida M., Ichikawa N., et al. Shear-induced von Willebrand factor-mediated platelet surface translocation of the CD40 ligand. Thromb Res 2003, 108:311-315.
19. Kato K., Ito H., Hasegawa K., et al. Modulation of the stress-induced synthesis of hsp27 and alpha B-crystallin by cyclic AMP in C6 rat glioma cells. J Neurochem 1996, 66:946-950.
20. Catella F., Healy D., Lawson J.A., FitzGerald G.A. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986, 83:5861-5865.
21. Smith C.J., Zhang Y., Koboldt C.M., et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998, 95:13313-13318.
22. Naito J., Komatsu H., Ujiie A., et al. Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur J Pharmacol 1983, 91:41-48.
23. Nicolaou K.C., Magolda R.L., Smith J.B., et al. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci USA 1979, 76:2566-2570.
24. Bertelé V., Di Minno G., de Gaetano G. U-46619, a stable analogue of prostaglandin H2, induces retraction of human platelet-rich plasma clots. Thromb Res 1980, 18:543-545.
25. Egan K., FitzGerald G.A. Eicosanoids and the vascular endothelium. Handb Exp Pharmacol 2006, 176:189-211.
26. Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982, 69:1366-1372.
27. Capone M.L., Tacconelli S., Sciulli M.G., et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004, 109:1468-1471.
28. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008, 118:18-35.
29. Cuenda A., Rouse J., Doza Y.N., et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995, 364:229-233.
30. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494.
31. Bennett B.L., Sasaki D.T., Murray B.W., et al. Anderson DW SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001, 98:13681-13686.
32. Liu J., Pestina T.I., Berndt M.C., et al. The roles of ADP and TXA2 in botorocatin/VWF-induced aggregation of washed platelets. J Thromb Haemost 2004, 2:2213-2222.
33. Pignatelli P., Sanguigni V., Lenti L., et al. gp91phoz-dependent expression of platelet CD40 ligand. Circulation 2004, 110:1326-1329.
34. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987, 316:1371-1375.
35. Korshunov V.A., Schwartz S.M., Berk B.C. Vascular remodeling: hemodynamic and biochemical mechanisms underlying Glagov's phenomenon. Arterioscler Thromb Vasc Biol 2007, 27:1722-1728.
36. Malek A.M., Alper S.L., Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999, 282:2035-2042.
37. Kroll M.H., Hellums J.D., Mclntire L.V., Schafer A.I., Moake J.L. Platelets and shear stress. Blood 1996, 88:1525-1541.
38. Holme P.A., Orvim U., Hamers M.J., et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997, 17:646-653.
39. Maalej N., Holden J.E., Folts J.D. Effects of shear stress on acute platelet thrombus formation in canine stenosed carotid arteries: an in vivo quantitative study. J Thromb Thrombolysis 1998, 5:231-238.
40. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
41. Nakamura T., Jamieson G.A., Okuma M., Kambayashi J., Tandon N.N. Platelet adhesion to native type I collagen fibrils. Role of GPVI in divalent cation-dependent and -independent adhesion and thromboxane A2 generation. J Biol Chem 1998, 273:4338-4344.
42. Cipollone F., Mezzetti A., Porreca E., et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002, 106:399-402.
43. Semb A.G., van Wissen S., Ueland T., et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 2003, 41:275-279.
44. Furberg C.D., Adams H.P., Applegate W.B., et al. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events, Aymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994, 90:1679-1687.
45. Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577-581.
46. MacMahon S., Sharpe N., Gamble G., et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998, 97:1784-1790.
47. Reid J.A., Wolsley C., Lau L.L., et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. Eur J Vasc Endovasc Surg 2005, 30:464-468.
48. Amarenco P., Bogousslavsky J., Callahan A. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.
49. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.